EQ
EQ
Equillium, Inc.
$2.81
0.00%
$177.7M
No data for this timeframe.
Vol
Market Cap$177.7M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders30 funds
Inst. Value$48.5M
Inst. Activity0 buys / 1 sells
Insider Activity0B / 10S
Insider Net $-$2.2M
Reddit Sentiment50° Neutral
SEC Reports6
Press Releases2
Recent Activity
Jun 11, 2026
SEC
Three major passive institutions (Vanguard, State Street, Morgan Stanley) added to their Equillium positions during Q3 2
INST-CLUSTER — Impact 3/10
Jun 5, 2026
SEC
Three Equillium insiders, including the President/CSO, COO, and Principal Accounting Officer, sold a total of ~$975K in
CLUSTER — Impact 5/10
Jun 5, 2026
Insider
Zedelmayer Christine sold 14,584 shares
Sr. Vice President and COO @ $2.93 ($42.7K)
Jun 5, 2026
Insider
Zedelmayer Christine acquired via exercise 14,584 shares
Sr. Vice President and COO @ $0.7850 ($11.4K)
Jun 5, 2026
Insider
Connelly Stephen sold 30,975 shares
President and CSO @ $2.94 ($91.1K)
Jun 2, 2026
other
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnolo
May 29, 2026
SEC
Two Equillium insiders (COO and Principal Accounting Officer) sold a combined $342K in open-market sales on May 28, 2026
CLUSTER — Impact 4/10
Inst.
MORGAN STANLEY — TRIM
18,520 shares ($37.0K)
Price Targets
$7.13
+153.6% upside
Strong Buy
Current $2.81
Low $4.00
Median $6.50
High $12.00
8 analysts
$4.00
$12.00
Analyst Ratings
7Strong Buy
7Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 2, 2026 | Roth Capital | REITERATE | Buy → Buy |
| May 28, 2026 | Leerink Partners | UPGRADE | Market Perform → Outperform |
| May 28, 2026 | Roth Capital | REITERATE | Buy → Buy |
| Apr 17, 2026 | Roth Capital | REITERATE | Buy → Buy |
| Apr 16, 2026 | B. Riley Securities | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.06 ▼ -39.6% | $-0.10 — $-0.05 | 62% YoY | 7 |
| Next Q | $-0.05 ▲ +10.7% | $-0.08 — $0.00 | 17% YoY | 7 |
| Current FY | $-0.24 ▼ -11.5% | $-0.31 — $-0.18 | 38% YoY | 6 |
| Next FY | $-0.26 ▼ -4.7% | $-0.43 — $-0.15 | -8% YoY | 6 |
Latest Reports
NEUTRAL
INST-CLUSTER
3/10
Three major passive institutions (Vanguard, State Street, Morgan Stanley) added to their Equillium positions during Q3 2
Jun 11, 2026
BEARISH
CLUSTER
5/10
Three Equillium insiders, including the President/CSO, COO, and Principal Accounting Officer, sold a total of ~$975K in
Jun 5, 2026
NEUTRAL
Press
3/10
Equillium announced a virtual investor event on May 27, 2026, to present new preclinical data on AhR modulators and the
May 20, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| JANUS HENDERSON GROUP PLC | $13.0M | — |
| ADAGE CAPITAL PARTNERS GP, | $10.7M | — |
| Woodline Partners LP | $7.0M | — |
| RA CAPITAL MANAGEMENT, L.P. | $6.2M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | Zedelmayer Christine | SELL | $42.7K |
| Jun 5, 2026 | Zedelmayer Christine | M | $11.4K |
| Jun 5, 2026 | Connelly Stephen | SELL | $91.1K |
| Jun 4, 2026 | Connelly Stephen | SELL | $632.8K |
| May 28, 2026 | Troupin Barbara | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
30 institutional holders with $48.5M total value (24,284,554 shares) as of 2026-Q1. Top holders: ROYAL, JANUS, ADAGE. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 105 | $0.00 | 0.0% | — |
| 2 | JANUS HENDERSON GROUP PLC | 6,494,571 | $13.0M | 26.7% | — |
| 3 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,329,416 | $10.7M | 22.0% | — |
| 4 | Woodline Partners LP | 3,500,901 | $7.0M | 14.4% | — |
| 5 | RA CAPITAL MANAGEMENT, L.P. | 3,096,336 | $6.2M | 12.8% | — |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 1,784,472 | $3.6M | 7.4% | — |
| 7 | BALYASNY ASSET MANAGEMENT L.P. | 1,638,770 | $3.3M | 6.8% | — |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 656,964 | $1.3M | 2.7% | DOUBLED +124.3% |
| 9 | Hudson Bay Capital Management LP | 428,538 | $857.1K | 1.8% | ADD +53.9% |
| 10 | TWO SIGMA INVESTMENTS, LP | 246,173 | $492.3K | 1.0% | DOUBLED +144.1% |
| 11 | VANGUARD FIDUCIARY TRUST CO | 189,530 | $379.1K | 0.8% | — |
| 12 | STATE STREET CORP | 174,060 | $348.1K | 0.7% | DOUBLED +130.3% |
| 13 | CITADEL ADVISORS LLC | 158,733 | $317.5K | 0.7% | TRIM -34.5% |
| 14 | BlackRock, Inc. | 127,852 | $255.7K | 0.5% | — |
| 15 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 115,535 | $231.1K | 0.5% | — |
| 16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 77,300 | $154.6K | 0.3% | — |
| 17 | MARSHALL WACE, LLP | 57,632 | $115.3K | 0.2% | — |
| 18 | OMERS ADMINISTRATION Corp | 50,037 | $100.1K | 0.2% | — |
| 19 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 38,200 | $76.4K | 0.2% | — |
| 20 | CITADEL ADVISORS LLC | 31,200 | $62.4K | 0.1% | TRIM -34.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 35,734 | 18,520 | -48.2% | $37.0K | 2026-Q1 |
| VANGUARD GROUP INC | ADD | 1,313,946 | 1,920,423 | +46.2% | $3.0M | 2025-Q4 |
| Hudson Bay Capital Management LP | ADD | 278,538 | 428,538 | +53.9% | $664.2K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 133,004 | 324,610 | +144.1% | $503.1K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 10,085 | 35,734 | +254.3% | $55.4K | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 824,091 | 1,313,946 | +59.4% | $1.9M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 274,100 | 614,923 | +124.3% | $879.3K | 2025-Q3 |
| STATE STREET CORP | DOUBLED | 59,720 | 137,520 | +130.3% | $196.7K | 2025-Q3 |
| CITADEL ADVISORS LLC | TRIM | 130,705 | 85,557 | -34.5% | $122.3K | 2025-Q3 |
| UBS Group AG | TRIM | 83,551 | 28,030 | -66.5% | $40.1K | 2025-Q3 |
| MORGAN STANLEY | ADD | 7,530 | 10,085 | +33.9% | $14.4K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 179 | 274 | +53.1% | $392.00 | 2025-Q3 |
| UBS Group AG | DOUBLED | 1,722 | 83,551 | +4752.0% | $26.3K | 2025-Q2 |
| MORGAN STANLEY | ADD | 6,885 | 10,238 | +48.7% | $4.0K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 17,309 | 1,722 | -90.1% | $675.00 | 2025-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 467 | 145 | -69.0% | $108.00 | 2024-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 158 | 467 | +195.6% | $388.00 | 2024-Q3 |
| HRT FINANCIAL LP | TRIM | 30,506 | 18,064 | -40.8% | $15.00 | 2024-Q3 |
8 unique insiders with 23 transactions. Net insider value: -$2.2M ($0.00 bought, $2.2M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Zedelmayer Christine | Sr. Vice President and COO | SELL | 14,584 | $2.93 | $42.7K |
| Jun 5, 2026 | Zedelmayer Christine | Sr. Vice President and COO | EXERCISE | 14,584 | $0.7850 | $11.4K |
| Jun 5, 2026 | Connelly Stephen | President and CSO | SELL | 30,975 | $2.94 | $91.1K |
| Jun 4, 2026 | Connelly Stephen | President and CSO | SELL | 200,000 | $3.16 | $632.8K |
| May 28, 2026 | Troupin Barbara | Director | AWARD | 70,000 | — | — |
| May 28, 2026 | BRADBURY DANIEL | CHAIRMAN | AWARD | 70,000 | — | — |
| May 28, 2026 | McDermott Charles Douglas | Director | AWARD | 70,000 | — | — |
| May 28, 2026 | Pruzanski Mark | Director | AWARD | 70,000 | — | — |
| May 28, 2026 | Zedelmayer Christine | Sr. Vice President and COO | EXERCISE | 7,292 | $0.7300 | $5.3K |
| May 28, 2026 | Zedelmayer Christine | Sr. Vice President and COO | SELL | 55,604 | $2.70 | $150.1K |
| May 28, 2026 | DEMSKI MARTHA J | Director | AWARD | 70,000 | — | — |
| May 28, 2026 | Tom Penny | Principal Accounting Officer | EXERCISE | 65,000 | $0.7850 | $51.0K |
| May 28, 2026 | Tom Penny | Principal Accounting Officer | SELL | 65,000 | $2.95 | $191.8K |
| May 27, 2026 | Zedelmayer Christine | Sr. Vice President and COO | EXERCISE | 9,821 | $0.7700 | $7.6K |
| May 27, 2026 | Zedelmayer Christine | Sr. Vice President and COO | SELL | 9,821 | $2.70 | $26.5K |
| Mar 13, 2026 | Zedelmayer Christine | Sr. Vice President and COO | EXERCISE | 120,312 | $0.7850 | $94.4K |
| Mar 13, 2026 | Zedelmayer Christine | Sr. Vice President and COO | SELL | 120,312 | $2.50 | $300.8K |
| Mar 9, 2026 | Zedelmayer Christine | Sr. Vice President and COO | EXERCISE | 35,695 | $0.7850 | $28.0K |
| Mar 9, 2026 | Zedelmayer Christine | Sr. Vice President and COO | SELL | 181,219 | $2.00 | $362.4K |
| Feb 19, 2026 | Zedelmayer Christine | Sr. Vice President and COO | EXERCISE | 109,375 | $0.7850 | $85.9K |
| Feb 19, 2026 | Zedelmayer Christine | Sr. Vice President and COO | SELL | 109,375 | $1.78 | $194.8K |
| Feb 19, 2026 | Zedelmayer Christine | Sr. Vice President and COO | EXERCISE | 109,375 | $0.7850 | $85.9K |
| Feb 19, 2026 | Zedelmayer Christine | Sr. Vice President and COO | SELL | 109,375 | $1.78 | $194.8K |
6 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 5 neutral. Avg impact: 3.8/10.
NEUTRAL
INST-CLUSTER
3/10
Three major passive institutions (Vanguard, State Street, Morgan Stanley) added to their Equillium p
Jun 11, 2026
BEARISH
CLUSTER
5/10
Three Equillium insiders, including the President/CSO, COO, and Principal Accounting Officer, sold a
Jun 5, 2026
NEUTRAL
CLUSTER
4/10
Two Equillium insiders (COO and Principal Accounting Officer) sold a combined $342K in open-market s
May 29, 2026
NEUTRAL
EFFECT
4/10
Equillium's S-3 shelf registration has become effective, allowing the company to sell up to $250 mil
Apr 17, 2026
NEUTRAL
DEFA14A
3/10
Equillium, Inc. is holding its annual meeting to vote on director elections, a reverse stock split,
Apr 15, 2026
NEUTRAL
S-3
4/10
Equillium filed an S-3 shelf registration to allow RA Capital Management to resell up to 18.88 milli
Apr 7, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 16 analysts: 7 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.13 mean target
+153.6% upside
Strong Buy (1.00)
$4.00 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $2.81 |
| Target Low | $4.00 |
| Target Mean | $7.13 |
| Target Median | $6.50 |
| Target High | $12.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.06 | $-0.10 | $-0.05 | 61.6% | -39.6% | 0↑ 4↓ | $0.0B | 0.0% | 7 |
| Next Q 2026-09-30 |
$-0.05 | $-0.08 | $0.00 | 16.7% | +10.7% | 1↑ 2↓ | $0.0B | 0.0% | 7 |
| Current FY 2026-12-31 |
$-0.24 | $-0.31 | $-0.18 | 38.0% | -11.5% | 2↑ 4↓ | $0.0B | 0.0% | 6 |
| Next FY 2027-12-31 |
$-0.26 | $-0.43 | $-0.15 | -8.3% | -4.7% | 2↑ 2↓ | $0.0B | 0.0% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.061 | |
| 7d ago | $-0.063 | +0.001 |
| 30d ago | $-0.044 | -0.017 |
| 60d ago | $-0.040 | -0.021 |
| 90d ago | $-0.065 | +0.004 |
4 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 3 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 2, 2026 | Roth Capital | REITERATE | Buy | Buy |
| May 28, 2026 | Leerink Partners | UPGRADE | Market Perform | Outperform |
| May 28, 2026 | Roth Capital | REITERATE | Buy | Buy |
| Apr 17, 2026 | Roth Capital | REITERATE | Buy | Buy |
| Apr 16, 2026 | B. Riley Securities | INITIATE | — | Buy |
| Apr 14, 2026 | Raymond James | INITIATE | — | Strong Buy |
| Mar 13, 2026 | Roth Capital | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% | |
| May 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% | |
| Apr 1, 2026 | 5 | 5 | 2 | 0 | 0 | 83% | |
| Mar 1, 2026 | 5 | 4 | 2 | 0 | 0 | 82% | |
| Feb 1, 2026 | 4 | 4 | 2 | 0 | 0 | 80% | |
| Jan 1, 2026 | 4 | 4 | 2 | 0 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
1 mentions
0 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 27, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
Jun 2, 2026
other
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat s
May 28, 2026
other
Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
<p>LA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat se
May 28, 2026
short_volume
Short Volume: EQ — 71.8% short (0.8M / 1.1M)
Short: 816,022 | Exempt: 40,533 | TRF Vol: 1,137,254 | Short Ratio: 71.8% | Off-exchange volume (dark pool + OTC)
May 20, 2026
fda
Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis
Virtual webinar to be held on Wednesday, May 27 at 11:00 AM ET <pre>Virtual webinar to be held on Wednesday, May 27 at 11:00 AM ET</pre>
May 13, 2026
earnings
Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights
<p align="center"><em>Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereaft
May 13, 2026
earnings_calendar
EQ Q1 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
earnings_calendar
EQ Q1 2026 Earnings Scheduled — 2026-05-12
May 1, 2026
other
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>LA JOLLA, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat se
Apr 20, 2026
other
Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event
<p>LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat
Apr 8, 2026
routine
Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists
<p>LA JOLLA, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat
Apr 2, 2026
other
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>LA JOLLA, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat
Mar 25, 2026
earnings
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights
<p align="center"><em>Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months therea
Mar 25, 2026
earnings_calendar
EQ Q4 2025 Earnings After Market Close — 2026-03-25
Mar 18, 2026
other
Equillium to Participate in the 38th Annual Roth Conference
<p>LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat
Mar 13, 2026
other
Equillium Announces $35 Million Financing with RA Capital Management
<p align="center"><em>Capital strengthens the advancement of EQ504 through key clinical milestones</em></p>